Medtronic reported adjusted earnings of $1.55 per share, slightly above estimates, and revenue rose 9.9% year-over-year to $9.81 billion, driven by strong cardiovascular segment growth. BTIG upgraded Medtronic from Neutral to Buy, citing accelerating organic growth and undervaluation compared to peers. Leerink Partners lowered its price target to $104 but maintained an Outperform rating, highlighting Medtronic's strong commercial execution and growth potential. Shares rose 4.3% following the earnings beat and positive analyst commentary.
The global market for non-invasive blood glucose monitoring devices, which measure blood sugar without needles, is projected to grow from $34.86 million in 2024 to $340.49 million by 2034, at a CAGR of 25.6%. Growth is fueled by the increasing diabet...
Medtronic announced key FDA submissions and clearance for its Hugo robotic-assisted surgery system, expanding its use to general and gynecologic surgeries in the U.S. The company filed 510(k) clearances for general surgery, gynecologic procedures, an...
Medtronic announced strategic investments in two companies developing intracardiac echocardiography (ICE) catheter technologies, which provide real-time heart imaging during cardiac ablation procedures. These investments aim to integrate ICE into Med...
Medtronic reported its fiscal year 2026 revenue at $36.4 billion, marking the highest annual growth in a decade with an 8.4% increase as reported and 5.8% organic growth. The company saw strong performance across key segments like Cardiac Ablation So...
The global peripheral vascular devices market is projected to grow from $10.02 billion in 2026 to $13.22 billion by 2031, at a CAGR of 5.7%. Growth is fueled by rising cases of vascular disorders linked to aging, diabetes, and lifestyle factors, alon...
